MRVI logo

Maravai LifeSciences Holdings, Inc.

MRVI
Healthcare|Biotechnology|US
$7.52
+0.54 (+7.74%)
DCF Value
$2.43
Tangible Book / Share
$0.54
Cash / Share
$0.49

About

Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.

Stock Price

+160.2%(1Y)
1M
+4.3%
3M
+20.7%
6M
+55.1%
YTD
+131.4%
1Y
+142.6%
3Y
+60.0%
5Y
-79.0%

Pipeline Summary

0 total trials
0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4

Key Facts

Market Cap$2.13B
Employees435 (-24% YoY)
CEOBernd Brust
IPO DateNov 20, 2020
Beta0.62
52-Week Range$2.8 – $9.42
Avg Volume3,050,232
ExchangeNASDAQ

Ownership

Float71.4%
Shares Outstanding149.0M

Recent Insider Trades

Asarpota RajeshTAX W/H
Oct 30, 20265,466 shares @ $8.46
Brust BerndTAX W/H
Oct 8, 202629,250 shares @ $7.43
Asarpota RajeshTAX W/H
Sep 30, 20265,465 shares @ $7.65
Brust BerndTAX W/H
Sep 8, 202629,250 shares @ $7.32
Asarpota RajeshTAX W/H
Aug 31, 20265,465 shares @ $7.68

Peers

AZTAAzenta, Inc.
$1.72B
BIOBio-Rad Laboratories, Inc.
$10.25B
BLFSBioLife Solutions, Inc.
$1.89B
LABStandard BioTools Inc.
$251.0M
NEOGNeogen Corporation
$2.57B
PACBPacific Biosciences of California, Inc.
$700.9M
RGENRepligen Corporation
$11.09B
TECHBio-Techne Corporation
$11.43B
Data last updated: Nov 9, 2026, 04:23 AM